FinVector Vision Therapies Ltd (FinVector)

FinVector Vision therapies Ltd
Sanderum House
Oakley road
Chinnor OX39 4TW
United Kingdom

Main Website »

FinVector Vision Therapies Ltd (FinVector) is one of Europe's leading biotechnology companies exploiting gene therapy. FinVector has developed a serum-free single-use system cell suspension-based process (“ATOSUS”) for production of clinical grade replication-defective adenoviral vectors. This process is scalable for supply for subsequent larger clinical trials and commercial supply.

FinVector will manufacture and supply adenoviral VEGF vector for the project, including for reproductive toxicology studies, to cGMP when required for clinical use according to the international quality control standards.

Personnel Involved
Nigel Parker, Mark Docherty, Robert Shaw